Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.

NCT01091259 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT01091259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01091259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2010
Completion date
May 31, 2015
Enrollment
29 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma